Exosome and Stem Cell Therapy in London

In short

Exosome treatment and stem cell therapy are not the same thing, and the phrase exosome stem cell therapy conflates two categories that UK regulation treats very differently. Exosomes are extracellular vesicles released by cells. They are not cells, they do not divide and they cannot become anything.

The preparations used in London aesthetic clinics are derived from cultured cells, often mesenchymal stromal cells, but the material applied to your skin or scalp is the vesicle fraction rather than the cells themselves. That distinction is the difference between a cosmetic application and a class of medicine with a far stricter regulatory regime, which is why the vocabulary is worth pinning down before the price is discussed.

Two different things wearing one name

The phrase that brings most people to this page joins two categories that are related but not interchangeable. Understanding the join is the single most useful thing a patient can do before a consultation in this area, because almost every other question depends on it.

A stem cell is a cell. It is alive, it divides, and it can differentiate into other cell types. A therapy built on stem cells introduces living cells into the body with the intention that they persist and do something there. In the United Kingdom that class of treatment sits inside a strict framework, and legitimate use is largely confined to defined clinical settings with specific authorisations behind it.

An exosome is not a cell. It is a small membrane bound particle released by cells, typically tens to low hundreds of nanometres across, carrying proteins, lipids and nucleic acids and displaying surface proteins that govern which cells it docks with. It cannot divide, it cannot differentiate, and it does not persist as a living entity. It is a package of signalling material rather than a builder.

The preparations used in aesthetic clinics are produced from cultured cells, frequently mesenchymal stromal cells, and the material that reaches you is the vesicle fraction separated out from that culture. Calling the result stem cell therapy describes the manufacturing origin and misdescribes what is applied. Our main guide sets out the particle and the proposed mechanism in detail.

Why the wording is not a pedantic point

It matters for three practical reasons, all of which affect a patient rather than a regulator.

The first is regulatory. The two categories are governed differently in the UK, and a clinic using the language of one while supplying the other has either not understood the distinction or is relying on you not to press it. Either way it tells you something about the consultation you are about to have.

The second is expectation. Stem cell language implies regeneration in the strong sense, tissue being rebuilt by cells that took up residence. Nothing in an aesthetic exosome protocol supports that expectation. What is proposed is influence on an existing repair process, over months, partially.

The third is comparison. If you do not know which category you are being sold, you cannot compare two offers, and you certainly cannot compare prices. A term that covers both a licensed cell therapy and a topical vesicle preparation is not a term you can shop with.

Where UK regulation draws its lines

No exosome product currently holds a UK marketing authorisation as a medicine. Injection is not a licensed route for any of them, which is why the practical route in UK clinics is application after microneedling, where the barrier has been breached mechanically rather than pierced by a syringe.

Several frameworks overlap here rather than one rule applying cleanly. Medicines regulation attaches to how a product is presented and what it claims. Device regulation attaches to the needling equipment. Human tissue rules attach to material of human origin. Which of these applies to a given preparation depends on what it is and how it is described, which is exactly why a clinic should be able to say what the regulatory basis for its use is. The position should be verified with the Medicines and Healthcare products Regulatory Agency rather than assumed from marketing, and our regulation page works through the overlaps.

The consequence worth carrying into a consultation is simple. Where there is no licence there is no assessed dossier, no defined recall route and no regulator holding a file on the specific product. What remains is the professional regulator governing the practitioner, and the practitioner's willingness to answer the classification question directly.

What the treatment is proposed to do

The proposed mechanism is signalling. Vesicles carry material that can influence the behaviour of recipient cells, and the hypothesis in aesthetics is that applying them into freshly needled tissue influences the healing response in a favourable direction: more organised collagen deposition, a calmer inflammatory phase, a better quality repair.

That hypothesis is coherent and it is not fringe biology. What is missing is not plausibility but demonstration in this specific use, in humans, with preparations that are comparable to one another. The studies available are generally small, short and heterogeneous, and the preparations themselves differ in source cell, isolation method, concentration and storage. Two products both described as exosomes are not equivalent in any meaningful sense.

Our evidence page grades this qualitatively and declines to convert it into a percentage, because a percentage would imply a precision that the literature does not contain.

Reading a London regenerative offer

London carries the highest concentration of clinics working in this area in the UK, and the range of seriousness within it is wide. The same protocol appears under several names, prices vary by a factor of three for what is materially the same appointment, and the vocabulary borrows freely from clinical research.

The differentiator available to a patient is not the technology, because the technology is broadly similar. It is whether the clinic describes the category accurately. Practices operating in regenerative aesthetics in London, among them Mesglo London, tend to present these preparations as an emerging category rather than an established treatment, and that framing is the minimum a reader should expect wherever the treatment is offered. Its absence is the most useful signal available when comparing consultations. We assess nobody's results, we recommend no practice and we name no product.

Alongside that, check the person rather than the premises. Doctors appear on the General Medical Council register and nurses on the Nursing and Midwifery Council register. The Joint Council for Cosmetic Practitioners maintains a voluntary register with published standards alongside them.

Indicative UK costs in 2026

As ranges rather than quotations, with London at or above the top of each: a single full face session commonly falls between about £250 and £600, face and neck between about £350 and £750, and a course of three for the face between about £700 and £1,500. Application added to a laser, peel or needling appointment on the same visit is commonly quoted between about £100 and £300.

The comparison that isolates what you are paying for remains the same one. Microneedling alone commonly costs between about £150 and £350 a session in the UK. The gap between that and the protocol price is the preparation, and asking a clinic to state both numbers is a reasonable request that a serious practice will meet without difficulty. Our cost page sets out the full comparison, and the alternatives page places platelet rich plasma, polynucleotides and topical actives beside it by mechanism and regulatory status.

How to decide without deciding on vocabulary

Three questions cut through the terminology entirely. What is in this preparation, what is its source and how is it classified for use in the UK. Is anything living being introduced, and if not, why is the word stem cell being used. And what is the evidence for this preparation in the specific thing I am asking you to treat.

A practice that answers all three plainly is not necessarily the right choice, but it is a practice you can evaluate. One that cannot answer the first has not asked its own supplier. The consultation checklist on this site turns the same approach into twelve printable questions.

None of this is an argument that the category is worthless. It is an argument for buying what is actually being sold. The regenerative frontier is a real area of research and a genuinely interesting one. It is also, at present, a frontier, and a patient treated at a frontier is contributing to the evidence rather than drawing on it. That is a reasonable thing to choose. It is not a reasonable thing to be told about afterwards.

Common questions

Is exosome therapy the same as stem cell therapy?

No. Stem cells are living cells that divide and can differentiate. Exosomes are small membrane bound particles released by cells, carrying signalling material. They do not divide, do not differentiate and do not persist as living entities. Aesthetic preparations are derived from cultured cells, but the material applied is the vesicle fraction rather than the cells themselves, and the two are regulated very differently in the UK.

Is it legal to have this treatment in London?

Practitioners do offer these preparations, and the framework around them is not a single rule but several overlapping ones covering medicines, devices and material of human origin. No exosome product holds a UK marketing authorisation and injection is not a licensed route for any of them. A clinic should be able to say what the regulatory basis for its own use is, and the position should be verified with the MHRA rather than taken from marketing.

What results are realistic?

Gradual and partial change in skin quality or scalp condition over three to six months, difficult to separate from the effect of the microneedling used to deliver the material. It does not reposition tissue, it does not replace lost volume and it does not restore follicles that have gone. Anything described as regeneration in the strong sense is overstating what the mechanism supports.

Why do two clinics quote very different prices for the same thing?

Because the preparation, its concentration, the number of passes, the depth used, the seniority of the person treating you and the premises all vary, and none of that appears in a price list. Asking for the clinic's price for microneedling alone alongside its price for the protocol isolates what the preparation is costing you.

What should I do if something goes wrong afterwards?

Contact the treating practitioner first and, where you have symptoms that concern you, a doctor or NHS 111. Because these preparations are not licensed medicines there is no defined product recall route, but the practitioner remains accountable to their professional regulator, and suspected adverse reactions involving medicines and devices can be reported through the MHRA Yellow Card scheme.

Sources

Disclosure

Exosomes Therapy is independently published. This article carries one link to an external business. That link was placed for editorial reasons by the publisher, it was not sold, exchanged or paid for in any form, and the business concerned had no sight of this article before publication and no right of approval over it. Exosomes Therapy does not sell links, placements, reviews or coverage on any of its titles. The full position is set out in our editorial policy.

If you want to speak to someone

We are not a clinic and we give no medical advice. If you would like to, we can pass your details to a registered UK practitioner who will contact you directly. Nothing is booked on your behalf and there is no obligation. Read the regulation page first.

Make an enquiry

Exosome and stem cell therapy in London: what the regenerative frontier actually is